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Abstract
Background: Exercise has been studied as a prognostic marker for patients with cystic fibrosis (CF), as well as a tool
for improving their quality of life and analyzing lung disease. In this context, the aim of the present study was to
evaluate and compare variables of lung functioning. Our data included: (i) volumetric capnography (VCAP) parameters:
expiratory minute volume (VE), volume of exhaled carbon dioxide (VCO2), VE/VCO2, ratio of dead space to tidal volume
(VD/VT), and end-tidal carbon dioxide (PetCO2); (ii) spirometry parameters: forced vital capacity (FVC), percent forced
expiratory volume in the first second of the FVC (FEV1%), and FEV1/FVC%; and (iii) cardiorespiratory parameters: heart
rate (HR), respiratory rate, oxygen saturation (SpO2), and Borg scale rating at rest and during exercise. The subjects
comprised children, adolescents, and young adults aged 6–25 years with CF (CF group [CFG]) and without CF (control
group [CG]).
Methods: This was a clinical, prospective, controlled study involving 128 male and female patients (64 with CF) of a
university hospital. All patients underwent treadmill exercise tests and provided informed consent after study approval
by the institutional ethics committee. Linear regression, Kruskal–Wallis test, and Mann–Whitney test were performed to
compare the CFG and CG. The α value was set at 0.05.
Results: Patients in the CFG showed significantly different VCAP values and spirometry variables throughout the
exercise test. Before, during, and after exercise, several variables were different between the two groups; statistically
significant differences were seen in the spirometry parameters, SpO2, HR, VCO2, VE/VCO2, PetCO2, and Borg scale rating.
VCAP variables changed at each time point analyzed during the exercise test in both groups.
Conclusion: VCAP can be used to analyze ventilatory parameters during exercise. All cardiorespiratory, spirometry, and
VCAP variables differed between patients in the CFG and CG before, during, and after exercise.
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Background
The role of exercise as a prognostic indicator and/or
therapeutic instrument is of interest in the research of
several diseases, particularly respiratory diseases. Over the
past three decades, exercise has become well established
as an important component in the management of cystic
fibrosis (CF) [1].
From birth, patients with CF undergo progressive de-
terioration of lung structures [1-5]. This deterioration of
anatomical structures causes functional changes directly
related to respiratory function. Changes include decreases
in the peripheral oxygen saturation (SpO2), forced
expiratory volume in the first second of the forced vital
capacity (FEV1), ratio of dead space to tidal volume
(VD/VT) and exercise performance, increases in the
* Correspondence: paloma.francisco@hotmail.com; fernandolimamarson@
hotmail.com
1Department of Pediatrics, State University of Campinas, Tessália Vieira de
Camargo 126, Cidade Universitária “Zeferino Vaz”, 13083-887 Campinas, SP,
Brazil
Full list of author information is available at the end of the article
© 2015 Parazzi et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Parazzi et al. BMC Pulmonary Medicine  (2015) 15:63 
DOI 10.1186/s12890-015-0056-5
respiratory rate (RR) and heart rate (HR), and changes
in blood gas parameters.
The benefits of exercise in patients with CF include
improved aerobic conditioning, decreased progression of
lung disease, and enhanced bronchial hygiene through
an increased ciliary beat frequency, activation of immune
cells, reduced susceptibility to viral infections, and
increased anti-inflammatory activity. Thus, patients
experience a better quality of life [1,6-8].
The exercise stress test has been increasingly used to
assess the level of exercise intolerance in patients with
heart and lung diseases. This test is considered the gold
standard for the study of exercise limitations and their
causes [9,10].
Volumetric capnography (VCAP) analyzes the pattern
of elimination of carbon dioxide (CO2) in the expired air
volume and can reveal a link between early structural
damage and functional lung abnormalities in patients
with CF. Previous studies have evaluated VCAP as a tool
for assessing the degree of regional heterogeneity of lung
gas exchange [11-13]. Some studies have found a rela-
tionship between VCAP parameters and pulmonary
involvement indices derived from VCAP [14-16]. The
curve of expired CO2 over time, known as a capnograph,
can show temporal changes in obstructive lung disease.
Besides the volume of exhaled CO2 (VCO2), VCAP mea-
sures the expiratory minute volume (VE), HR, RR, SpO2,
end-tidal CO2 (PetCO2), and VD/VT ratio, which in
normal subjects decreases during exercise and increases
when imbalance occurs [17,18].
Ribeiro et al. [19] recently compared VCAP and spir-
ometry in 64 children and adolescents with CF and 94
healthy subjects. Patients with CF showed a higher
slope3/VT than did healthy subjects. VCAP also showed
a difference in the slope3/VT in patients with CF who
had normal spirometry results, indicating an early
periphery airway dysfunction. An increased slope3/VT
reflects inhomogeneity of ventilation in the distal air-
ways, suggesting the possibility of chronic structural
dysfunction as well as reversible acute dysfunction that
may be observed, for example, in a bronchoprovocation
test. This index may be a useful tool in the evaluation
and study of small airway dysfunction in children and
adolescents with pulmonary disease.
The positive impact of regular physical activity and the
need for information about its effects justify the growing
interest in studies on regular exercise as a part of
treatment for patients with CF and as a tool to assess
pulmonary deterioration. This illustrates the relevance of
correlating the exercise stress test results with prognos-
tic indices obtained by VCAP. Moreover, comparison of
the results obtained from these tests between patients
with CF and healthy individuals demonstrates the im-
portance of physical and pulmonary rehabilitation and
justifies the incorporation of exercise in the routine
treatment of patients with CF.
In this context, the aim of this study was to evaluate
VCAP parameters (VE, VCO2, VD/VT, VE/VCO2, and
PetCO2) and cardiorespiratory parameters (HR, RR, and
SpO2) at rest and during the 6-minute walk test between
patients with CF and healthy subjects and to compare
these values with spirometry data and clinical markers.
Methods
This clinical, prospective, controlled study involved male
and female patients with CF (CF group [CFG]) from a uni-
versity hospital and healthy volunteers (control group [CG]).
All patients with CF who agreed to participate were
included. All patients aged >18 years and the caregivers
of patients aged <18 years provided written informed
consent. The inclusion criteria were an age of 6–25 years
and the presence of CF diagnosed according to the
criteria of the international consensus [20,21] by a sweat
test with a chloride level of >60 mEq/L and positive
genetic screening for the CF transmembrane regulator
(CFTR) mutation [20,22], when possible.
Patients were not in a state of pulmonary exacerbation
as verified by the application of two clinical scores: the
Cystic Fibrosis Foundation Clinical Score and the Cystic
Fibrosis Clinical Score [23,24]. The CG included children,
adolescents, and young adults aged 6–25 years who were
randomly selected among students from public and pri-
vate schools in the same university district. All partici-
pants answered a questionnaire, and no subjects had other
acute or chronic diseases.
The exercise stress test was performed on a treadmill
(Pro Cl 5004; Caloi-Electronic, Wallbach, Switzerland).
The velocity was increased according to each individual’s
tolerance level until a submaximal test level was reached;
at no time during the test did any individual exceed 75%
of their maximum HR, which was calculated by 220 − the
age of the individual [25].
Before starting the exercise test, all patients in the CFG
and CG underwent spirometry according to the guidelines
of the European Respiratory Society and American Thoracic
Society. The test started by measuring cardiorespiratory
variables at rest for 3 minutes; this was followed by
measurements during exercise testing on the treadmill for
6 minutes and immediately at the end of the test for a
further 3 minutes. Patients in both the CG and CFG
followed the same test sequence. The same trained profes-
sional performed all examinations.
Initial spirometry was performed using a model CPFS/
D spirometer (MedGraphics, Saint Paul, MN, USA) with
PF BREEZE Software, Version 3.8B for Windows 95/98/
NT (MedGraphics).
For VCAP, the CO2SMO Plus DX 8100 monitor
(Novametrix Medical Systems, Wallingford, CT, USA)
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was used. This is a noninvasive monitor with a capno-
graph, pulse oximeter, and pneumotachograph. The
monitor is connected to CO2 flux and pulse oximetry
sensors. The CO2 and flow sensors were used in all sub-
jects and discarded after each use according to the specifi-
cations in the manual. These flow and CO2 sensors are
combined at their distal portions and coupled to a nozzle.
The pediatric/adult (#6719) model of the flow sensor
was used. Capnography and pneumotachography mea-
sures were obtained in real time by analyzing the gases
breathed. The CO2SMO Plus was connected to a com-
puter equipped with software to record the flow, volume,
pressure, pressure–volume, flow–volume, and capnogra-
phy measurements and curves.
The sensor monitor was connected to a mouthpiece,
and a nose clip was used to prevent air escaping. Partici-
pants were seated in a quiet room and breathed for 1 mi-
nute to adapt to the equipment. The monitoring was
then started with Analysis Plus® software. Participants
maintained normal, relaxed breathing for 4 minutes, and
the variables were recorded and stored on the computer.
At the end of the data collection, an offline sequence of
breaths was selected to determine the coefficient of vari-
ation for the lowest expired VT of 25% of the average VT;
for PetCO2, measured in mmHg, a lower coefficient of
variation of 10% was permitted. Breaths that presented a
value of zero for the slope3 variable were excluded. The
results were obtained through the average of the parame-
ters collected during the 4-minute monitoring.
The analysis of expiratory gases was performed through-
out the test, with each patient using his or her own
mouthpiece and nose clip from beginning to end. All
subjects received prior clarification regarding the test to
be performed.
Statistical analysis
For patients in both the CG and CFG, statistical analysis
was performed at five different time points during the
exercise test: (1) baseline, (2) 1–2 minutes of activity, (3)
3–4 minutes of activity, (4) 5–6 minutes of activity, and
(5) immediately postexercise. The data were processed
using Statistical Package for Social Sciences, Version
21.0 software (SPSS Inc., Chicago, IL, USA). For numer-
ical data, the mean, confidence interval, standard devi-
ation, median, and minimum and maximum values were
used. For categorical data, the absolute number and per-
centage were used.
Comparisons between the CG and CFG were per-
formed with the Mann–Whitney test for variables with a
numeric distribution, and calculations of differences in
categorical variables between the CG and CFG were per-
formed with the χ2 test. Correlations between these time
points in each group were determined using the Friedman
test (non-parametric, repeated measures), and in cases
with a positive p-value, the Wilcoxon signed-rank test
was performed. Linear regression was performed to
compare the FEV1% and the VCAP parameter VCO2 at
all time points analyzed. Linear regression was also per-
formed to evaluate VCO2 in relation to the body mass
index (BMI) of all subjects.
For all analyses, we used a value of α = 0.05 with correc-
tion for multiple testing by the Bonferroni method (α =
0.05 / 5 = 0.01).
The research ethics committee of the State University
of Campinas (#1182/2009) approved this study.
Results
In total, 64 patients with CF and 64 healthy volunteers of
both sexes with no statistical differences in age or sex were
included in the study (p > 0.05). The complete genotypes of
mutations in the CFTR gene are shown in Additional file 1:
Table S1. A description of each identified mutation in the
CFTR gene is presented in Additional file 2: Table S2.
Weight (kg), height (m2), and BMI (kg/m2) were sig-
nificantly lower in the CFG (34.80 ± 13.30, 1.42 ± 0.19,
and 16.72 ± 3.15, respectively) than in the CG (46.39 ±
14.44, 1.52 ± 0.13, and 19.56 ± 3.33, respectively) (p ≤
0.001) (Table 1).
The Shwachman–Kulczycki score in the CFG ranged
from 60 to 90 (77.93 ± 6.94) (Table 1).
In both groups, assessment of dyspnea using the modi-
fied Borg scale (Table 1) showed statistically significant
differences before (p ≤ 0.001) and after testing (p ≤ 0.005).
Spirometric values at rest for both groups are shown
in Table 1. Patients in the CFG had a significantly lower
FVC, FEV1, and FEV1/FVC: (78.61 ± 20.68, 68.98 ± 22.45,
and 85.66 ± 11.56, respectively) than did patients in
the CG (95.78 ± 11.56, 91.94 ± 16.96, and 98.23 ± 8.95,
respectively) (p ≤ 0.001) (Table 1).
The complete list of VCAP values according to the
time of analysis between the CG and CFG is shown in
Additional file 3: Table S3.
The RR was higher in the CFG than in the CG at all
times analyzed, but the differences were not statistically
significant (Figure 1).
The HR was not different between the two groups at
any time points analyzed (p > 0.05). The SpO2 was lower
in the CFG (93.98 ± 7.22) than in the CG (95.90 ± 5.32),
but the difference between time points 4 and 5 was not
statistically significant (p ≤ 0.001) (Figure 1B, 1C).
There was an association between the distribution of
FEV1(%) and VCO2 at all times during the 6-minute
walk test (Figure 2).
The VE/VCO2 increased throughout the test and de-
creased at the end in both groups, but without statistical
significance (Figure 3A).
The Exhaled VCO2 increased in both groups and de-
creased at the end of the test, with statistical differences
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at all time points analyzed; higher values were observed
in the CG (391.16 ± 128.98) than in the CFG (338.03 ±
117.55) (p ≤ 0.001) (Figure 3B).
The PetCO2 increased over time; higher values were
observed in the CG (42.00 ± 3.82) than in the CFG
(38.41 ± 5.73) (p ≤ 0.001) (Figure 3C).
The VD/VT ratio decreased over time and then returned
to baseline; higher values were observed in the CFG,
but without statistical significance (p > 0.05) (Figure 3D).
The VE/VCO2 ratio decreased during the test and
increased at the end. A statistically significant differ-
ence was observed at all time points analyzed, and
patients in the CFG had higher ratios at the end of the
test (38.81 ± 8.83) than did patients in the CG (32.72 ±
4.74) (p ≤ 0.001) (Figure 4A). The distribution of FEV1(%)
showed an inverse association with the VE/VCO2 at
time points 1 and 5 in both the CFG and CG (Figure 4B
and C).
Table 1 Distribution of patients with cystic fibrosis and healthy subjects according to clinical laboratory markers
Marker Patients with cystic fibrosis Healthy subjects p-value
Sex (male) 32 (51.61) 30 (48.39) 0.860
Sex (female) 32 (48.50) 34 (51.50)
Age (years) 12.34 (11.48–13.21) ± 3.47 13.51 (12.34–14.68) ± 4.64 0.490
12.00 (6.00–23.00) 11.00 (9.00–25.00)
Weight (kg) 34.80 (31.47–38.12) ± 13.30 46.39 (42.75–50.02) ± 14.44 ≤0.001
33.75 (12.70–74.20) 44 (25.80–87.90)
Height (m) 1.42 (1.37–1.46) ± 0.19 1.52 (1.49–1.56) ± 0.132 0.003
1.45 (1.00–1.74) 1.58 (1.20–1.87)
BMI 16.72 (15.93–17.50) ± 3.15 19.56 (18.72–20.40) ± 3.33 ≤0.001
15.87 (11.30–28.63) 19.01 (13.46–27.13)
Shwachman–Kulczycki score 77.93 (76.20–79.67) ± 6.94 – –
80.00 (60.00–90.00) –
FVC% 78.61 (73.44–83.78) ± 20.68 95.78 (92.89–98.67) ± 11.56 ≤0.001
80.50 (32.00–121.00) 93.00 (69.00–130.00)
FEV1% 68.98 (63.38–74.59) ± 22.45 91.94 (87.70–96.17) ± 16.96 ≤0.001
65.50 (19.00–117.00) 90.00 (41.00–125.00)
FEV1/FVC 85.66 (82.77–88.54) ± 11.56 87.50 (52.00–107.00) 98.23 (95.99–100.47) ± 8.95 100.00 (74.00–125.00) ≤0.001
Borg rating (initial) <0.001
0 48 (75.0%) 64 (100.0%)
1 12 (19.0%) 0 (0.0%)
2 3 (5.0%) 0 (0.0%)
3 1 (1.0%) 0 (0.0%)
Borg rating (end)
0 33 (52.0%) 56 (88.0%)
1 6 (9.0%) 1 (1.0%)
2 14 (22.0%) 4 (6.3%)
3 6 (9.0%) 0 (0.0%)
4 2 (3.0%) 0 (0.0%) ≤0.005
5 1 (1.0%) 0 (0.0%)
6 1 (1.0%) 2 (3.0%)
7 0 (0.0%) 1 (1.0%)
10 1 (1.0%) 0 (0.0%)
FVC, forced vital capacity; FEV1, forced expiratory volume in the first second of the FVC; BMI, body mass index. For sex and the Borg scale rating, the data are
presented as n (%). For variables with numeric distribution, the data are presented as mean (confidence interval) ± standard deviation and median (minimum–maximum).
Differences between patients with CF and healthy subjects were calculated by the χ2 test for categorical variables and by the Mann–Whitney test for numerical data not
normally distributed (α = 0.05).
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Linear regression of VCO2 in relation to BMI is shown
in Additional file 4: Figure S4
All children completed the test without exhibiting car-
diorespiratory symptoms requiring cessation of the test.
Discussion
Exercise has been studied as a tool with which to assess
the improvement or worsening of cardiorespiratory
function [26-29]. To the best of our knowledge, this is
Figure 1 Comparison of cardiorespiratory variables between the group of patients with cystic fibrosis (CFG) (n=64) and the control group (CG)
(n=64). Data are presented as the confidence interval of the median. Time points analyzed: (1) baseline (rest), (2) 1–2 min of activity, (3) 3–4 min
of activity, (4) 5–6 min of activity, and (5) postexercise. α=0.01 by Bonferroni correction. The Mann–Whitney test was used to compare the CFG
and CG, and correlations between the time points in each group were determined using the Friedman test (non-parametric, repeated measures);
in cases with a positive p-value, the Wilcoxon signed-rank test was performed. (A) Respiratory rate. There was no difference between the CG and
CFG for the time points analyzed. In the cluster analysis for the CFG, time point 1 differed from 2 to 4; time point 2 differed from 1; time points
3 and 4 differed from 1 and 5; and time point 5 differed from 3 and 4 (p≤0.001). In the cluster analysis for the CG, time points 3 and 4 differed
from 5, and time point 5 differed from 3 and 4 (p≤0.001). (B) Heart rate. There was no difference between the CG and CFG for the time points
analyzed. In the cluster analysis for the CFG, time point 1 differed from 2 to 4; time point 2 differed from 1, 4, and 5; time point 3 differed from 1
and 5; time point 4 differed from 1, 2, and 5; and time point 5 differed from 2 to 4 (p≤0.001). In the cluster analysis for the CG, time point 1
differed from 2 to 5; time point 2 differed from 1, 3, 4, and 5; time points 3 and 4 differed from 1, 2, and 5; and time point 5 differed from 1 to
4 (p≤0.001). (C) Transcutaneous oxygen saturation. There was no difference between the CG and CFG for time points 4 and 5. For the other time
points, the CG exhibited higher values (time points 1 and 2, p≤0.001; time point 3, p=0.002). In the group analysis for the CFG, time point 1
differed from 2 and 4; time point 2 differed from 1 and 5; time point 3 differed from 5; time point 4 differed from 1 and 5; and time point 5
differed from 2 to 4 (p≤0.001). In the CG, time point 1 differed from 2 to 5 (p≤0.001).
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the first study to evaluate ventilatory efficiency through the
use of VCAP before, during, and after exercise between
patients with and without CF. Furthermore, it reinforces
the positive effects of the association between exercise and
therapy in these patients. Few studies have been conducted
using VCAP for evaluation of CF [19,30,31].
Our results reinforce the importance of exercise as a
useful tool in cardiorespiratory evaluation of patients
with CF. All cardiorespiratory, spirometry, and VCAP
markers differed between the CFG and CG before and
after exercise.
It is well known that CF causes progressive deterior-
ation in the ability to perform physical exercise. How-
ever, regardless of severity, both children and adults may
develop increased ability to tolerate exercise and benefit
from it in the long term [28].
Various authors have studied transverse or longitu-
dinal models and the benefits of exercise on lung func-
tion in patients with severe CF [27,29]. However, our
population of patients with CF had higher FEV1 values
than those in other studies [26,27]. This reflects a popu-
lation with minor deterioration in lung function. There
are several potential explanations for this difference; for
example, the patients in our center received medications
at no cost and underwent care by multidisciplinary
teams, the CFTR mutations belonged to different classes,
early diagnosis was achieved, interdisciplinary monitor-
ing was performed, and the patients included in our
study were relatively young.
Various markers of the deterioration of lung function in
patients with CF have been investigated and include
clinical and tomographic scores, spirometry values, VCAP
CFG
CG
Figure 2 Distribution points for linear regression of FEV1% and VCO2. A. Time point 1 - [Combined: y = 0.599 x + 134.183 (p = 0.011); R
2 = 0.0495],
[CF: y = 0.547 x + 132.642 (p = 0.091); R2 = 0.045], [Control: y = 197.146 – 0.0195 x (p = 0.973); R2 = 0.000018]. B. Time point 2 - [Combined: y = 1.290 x +
196.511 (p = 0.0006); R2 = 0.09095], [CF: y = 1.408 x + 184.347 (p = 0.005); R2 = 0.1198], [Control: y = 291.749 + 0.313 x (p = 0.736); R2 = 0.001876]. C. Time
point 3 - [Combined: y = 1.695 x + 234.349 (p = 0.001); R2 = 0.079], [CF: y = 1.256 x + 254.893 (p = 0.063); R2 = 0.05544], [Control: y = 254.560 + 1.584 x
(p = 0.253); R2 = 0.02173]. D. Time point 4 - [Combined: y = 1.805 x + 269.757 (p = 0.005); R2 = 0.06034], [CF: y = 1.219 x + 300.252 (p = 0.164); R2 = 0.03098],
[Control: y = 2.114 x + 250.909 (p = 0.189); R2 = 0.02815]. E. Time point 5 - [Combined: y = 237.724 + 1.548 x (p = 0.002); R2 = 0.0740], [CF: y = 251.939 +
1.248 x (p = 0.058); R2 = 0.05680], [Control: y = 249.636 + 1.492 x (p = 0.244); R2 = 0.02256].
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values, the lung clearance index, and others [19]. One
confirmed paradigm is that high-resolution computed
tomography detects changes in lung function earlier
than does spirometry, which illustrates the need for new
tools with which to investigate lung function. The use of
VCAP has not been extensively studied in patients with
CF. Hopefully, it will become the focus of new studies
to enable more accurate diagnosis of early pulmonary
disease [19,30,31]. Thus, in the present study, VCAP
was analyzed as a practical, inexpensive, and easy-to-
perform method that can give important information
about ventilatory function.
Throughout the exercise test, we observed that the RR
and HR were higher in the CFG than in the CG at all
time points, and the HR was higher in the CG only im-
mediately after exercise. This finding is in agreement
with a recent study by Pereira et al. [8] in which 55
patients with CF and 185 healthy individuals were evalu-
ated during the 6-minute walk test. During the test,
patients with CF exhibited a lower SpO2 than did healthy
individuals. The same result was observed by Holland et
al. [32] in a study of 101 adults with moderate to severe
CF performing the 3-minute step test. The authors
reported that desaturation during the test was associ-
ated with long-term pulmonary deterioration and longer
hospitalization periods in adults with CF. In a study
by Pereira et al. [8], SpO2 remained stable during the
6-minute walk test.
Figure 3 Variables from volumetric capnography between the group of patients with cystic fibrosis (CFG) (n=64) and the control group (CG)
(n=64). Data are presented as the confidence interval of the median. Time points analyzed: (1) baseline (rest), (2) 1–2 min of activity, (3) 3–4 min
of activity, (4) 5–6 min of activity, and (5) postexercise. α=0.01 by Bonferroni correction. The Mann–Whitney test (data not normally distributed)
was used to compare the CFG and CG, and correlations between the time points in each group were determined using the Friedman test
(non-parametric, repeated measures); in cases with a positive p-value, the Wilcoxon signed-rank test was performed. (A) Expired minute volume
(VE). There was no difference between the CF and CFG for the different time points analyzed. In the cluster analysis, for the CFG, time point 1
differed from 2 to 5; time point 2 differed from 1, 4, and 5; time point 3 differed from 1 and 5; time point 4 differed from 1, 2, and 5; and time
point 5 differed from 1 to 4 (p≤0.001). For the CG, time point 1 differed from 2 to 5; time point 2 differed from 1, 3, 4, and 5; time point 3 differed
from 1, 2, and 5; and time point 5 differed from 1 to 4 (p≤0.001). (B) VCO2. Higher values were observed in the CG than CFG (time point: (1)
p=0.003; (2) p=0.005; (3) p=0.001; (4) p=0.002; (5) p≤0.001). In the cluster analysis, for the CFG, time point 1 differed from 2 to 5; time point 2
differed from 1, 3, 4, and 5; time point 3 differed from 1, 2, and 5; and time point 5 differed from 1 to 4 (p≤0.001). For the CG, time point 1
differed from 2 to 5; time point 2 differed from 1, 3, and 4; time points 3 and 4 differed from 1, 2, and 5; and time point 5 differs from 1, 3, and
4 (p≤0.001). (C) PetCO2. Higher values were observed in the CG than CFG (time point 1, p = 0.002; other time points, p≤0.001). In the cluster
analysis for the CFG, time point 1 differed from 2 to 4; time points 2 to 4 differed from 1 and 5; and time point 5 differed from 2 to 4 (p≤0.001).
For the CG, time point 1 differed from 2 to 4; time point 2 differed from 1, 4, and 5; time point 3 differed from 1 and 5; time point 4 differed from
1, 2, and 5; and time point 5 differed from 2 to 4 (p≤0.001). (D) VD/VT. There was no difference between the CG and CFG for the different time
points analyzed. In the cluster analysis for the CFG, time point 1 differed from 2 to 4; time point 2 differed from 1; time points 3 and 4 differed
from 1 and 5; and time point 5 differed from 3 and 4 (p≤0.001). For the CG, time point 1 differed from 2 to 5; time point 2 differed from 1; time
points 3 and 4 differed from 1 and 5; and time point 5 differed from 1, 3, and 4 (p≤0.001).























Figure 4 VE/VCO2 by confidence intervals in relation to different time points and linear regression for time points 1 and 5 with respect to FEV1%.
(A) Confidence interval of VE/VCO2 for the cystic fibrosis group (CFG) (n=64) and control group (CG) (n=64). Data are presented as the confidence
interval of the median. Time points analyzed: (1) baseline (rest), (2) 1–2 min of activity, (3) 3–4 min of activity, (4) 5–6 min of activity, and (5)
immediately postexercise. α=0.01 by Bonferroni correction. The Mann–Whitney test was used to compare the CFG and CG, and correlations
between the time points in each group were determined using the Friedman test (non-parametric, repeated measures); in cases with a positive
p-value, the Wilcoxon signed-rank test was performed. Higher values were observed in the CG at all time points (p≤0.001). In the cluster analysis
for the CFG, time point 1 differed from 2 to 5; time point 2 differed from 1 and 4; time point 3 differed from 1 and 5; time point 4 differed from
1, 2, and 5; and time point 5 differed from 1, 3, and 4 (p≤0.001). For the CG, time point 1 differed from 2 to 5; time point 2 differed from 1, 3, and 4;
time point 3 differed from 1, 2, and 4; time point 4 differed from 1, 2, 3, and 5; and time point 5 differed from 1 and 4 (p≤0.001). (B) Linear regression
of the VE/VCO2 and FEV1%. Time point 1 - [(Combined: y= 52.5615 – 0.1343x) (p≤0.0001); R
2=0.01522; (CFG: y= 51.8380 – 0.1139x) (p=0.0056);
R2=0.1122; (CG: y = 48.0635 – 0.0935x) (p=0.1756); R2=0.02986]. (C) Linear regression of the EV/VCO2 and FEV1%. Moment 5 - [(Combined: y= 47.2563 –
0.1411x) (p≤0.001); R2=0.1622; (CFG: y= 46.6691 – 0.1139x) (p=0.024); R2=0.08373; (CG: y= 35.5437 – 0.02961x) (p=0.5310); R2=0.006467].
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In the present study, evaluation of dyspnea using the
modified Borg scale showed that the highest dyspnea rat-
ings were found in the CFG before and after the test; this
is in agreement with the data reported by Pereira et al. [8].
With progressive deterioration of the lungs, the amount
of VD increases, requiring changes in ventilation to main-
tain adequate alveolar ventilation during exercise. Thus,
changes in lung function over time have been correlated
with changes in exercise capacity. CO2 retention during
the maximal exercise stress test also reportedly contrib-
uted to a faster rate of decline in FEV1% in a study of chil-
dren with CF aged 11–15 years [26].
Throughout our analysis, patients in the CFG showed
significantly greater retention of Exhaled VCO2 than did
patients in the CG, who exhaled larger amounts of
VCO2. This finding can be explained by dysfunction that
causes difficultly in gas exchange, such as disruption of
the lung architecture, destruction of parts of the capil-
lary bed, increased DS, and secretion retention [33-35].
In the present study, we chose not to correct the VCAP
values by the BMI because the lower value of BMI in the
CFG was associated with the patients’ clinical disease
status, was a common factor in the population tested,
and represented the clinical picture at each time point
analyzed. If such a correction were made, the obtained
data would mask the true severity of the disease.
Assessment of the cardiorespiratory responses of healthy
children during the maximal exercise test revealed that
the responses were higher for HR, RR, VCO2, VD/VT, and
PetCO2, while VT and PetCO2 showed a smaller increase
in children than in adults. At peak exercise, larger differ-
ences were observed in HR and VD/VT in children than
in adults, suggesting there is increased ventilation in the
anatomical VD [36].
Leroy et al. [27] studied the impact of dyspnea and
alveolar hypoventilation during exercise in 18 patients
with CF through a maximal exercise test on a cycle.
They found that during exercise, patients exhibited pro-
gressive increases in their VT, reaching a peak VT at
48% of FVC [27]. The VD/VT ratio also increased
during exercise and represented 34% of the VT [27].
A main limitation of our study is the exclusion of a
curve of normal VCAP values. Although our sample has
statistical power for analysis, future studies with larger
numbers of patients of the same age and CFTR mutation
class should be performed.
Conclusions
We conclude that VCAP can be used as a tool for analysis
of ventilatory efficiency during exercise. All cardiorespira-
tory, spirometry, and VCAP variables differed between
patients with CF and healthy subjects before and after
exercise. These results indicate imbalanced ventilation/
perfusion characterized by both hypoxemia and CO2 retention,
which compromises exercise tolerance in patients with
CF. Continued research of cardiorespiratory markers in
transverse and longitudinal models at rest and after exer-
cise is needed to better understand the deterioration of
lung function in patients with CF.
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